Top

Published in:

01-03-2007 | Original Article

Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters

Authors: Wen-Chiuan Tsai, Lai-Fa Sheu, Shin Nieh, Cheng-Ping Yu, Gung-Huan Sun, Yeh-Feng Lin, Ann Chen, Jong-Shiaw Jin

Published in: World Journal of Urology | Issue 1/2007

Abstract

EMMPRIN and fascin are important factors in tumor invasion and progression. We tested the hypothesis that expression of EMMPRIN and fascin correlate with clinicopathological parameters of renal cell carcinoma (RCC). Immunohistochemical analysis of EMMPRIN and fascin were performed in tissue microarrays of 100 surgical specimens, including 35 clear-cell RCC (CRCC), 21 clear-cell RCC with granular differentiation (GRCC), 12 chromophobe RCC (ChRCC), 8 papillary RCC (PRCC), 9 carcinoma of the collecting duct of Bellini (CDC), 10 clear-cell RCC with sarcomatoid differentiation (SRCC), and 6 metastatic RCC. Average immunoscores of EMMPRIN were 100.8 in CRCC, 195.2 in GRCC, 298.4 in ChRCC, 219.2 in PRCC, 186.1 in CDC, 226.9 in SRCC, and 151.7 in metastatic RCC. Among all included cases, average EMMPRIN immunoscores were 84.6 in grade I, 130.4 in grade II, 184.3 in grade III, and 223.5 in grade IV. Additionally, average immunostaining scores of fascin were 53.6 in CRCC, 289.3 in GRCC, 193.3 in ChRCC, 151.8 in PRCC, 181.3 in CDC, 275.4 in SRCC, and 131.7 in metastatic RCC. Average fascin immunoscores were 59.3 in grade I, 91.6 in grade II, 130.2 in grade III, and 194.7 in grade IV. Higher EMMPRIN and fascin immunoscores also correlated significantly with TNM stages and survival rates in RCC. Significant correlation was found between EMMPRIN and fascin expression. In conclusion, higher expression of EMMPRIN and fascin correlate significantly with histological grades, clinical stages, and survival rates of RCC

Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) World Health Organization classification of tumours. Pathology and genetics of tumors of the urinary system and male genital organs. IARC Press, Lyon, pp 10–34

Parkin DM, Pisani P, Lopez AD, Masuyer E (1994) At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int J Cancer 59:494–504PubMedCrossRef

Chen CJ, Chen CW, Wu MM, Kuo TL (1992) Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:888–892PubMed

Ficarra V, Righetti R, Martignoni G, D’Amico A, Pilloni S, Rubilotta E, Malossini G, Mobilio G (2001) Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urol Int 67:130–134PubMedCrossRef

Srigley JR, Hutter RV, Gelb AB, Henson DE, Kenney G, King BF, Raziuddin S, Pisansky TM (1997) Current prognostic factors—renal cell carcinoma: workgroup no. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80:994–996PubMedCrossRef

Flanigan RC (2004) Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res 10:6335S–6341SPubMedCrossRef

Guo H, Li R, Zucker S, Toole BP (2000) EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 60(4):888–891PubMed

Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270PubMedCrossRef

Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K (1995) The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55(2):434–439PubMed

10.

Himelstein BP, Canete-Soler R, Bernhard EJ, Muschel RJ (1994) Induction of fibroblast 92 kDa gelatinase/type IV collagenase expression by direct contact with metastatic tumor cells. J Cell Sci 107:477–486PubMed

11.

Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P (1990) A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348(6303):699–704PubMedCrossRef

12.

Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset P (1995) Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92(7):2730–2734PubMedCrossRef

13.

Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K (2006) High incidence of EMMPRIN expression in human tumors. Int J Cancer (in press)

14.

Jin JS, Hsieh DS, Lin YF, Wang JY, Sheu LF, Lee WH (2006) Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol 13:573–580PubMedCrossRef

15.

Adams JC (2004) Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 16:590–596PubMedCrossRef

16.

Duh FM, Latif F, Weng Y, Geil L, Modi W, Stackhouse T, Matsumura F, Duan DR, Linehan WM, Lerman MI et al (1994) cDNA cloning and expression of the human homolog of the sea urchin fascin and Drosophila singed genes which encodes an actin-bundling protein. DNA Cell Biol 13:821–827PubMedCrossRef

17.

Grothey A, Hashizume R, Sahin AA, McCrea PD (2000) Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 83:870–873PubMedCrossRef

18.

Roma AA, Prayson RA (2005) Fascin expression in 90 patients with glioblastoma multiforme. Ann Diagn Pathol 9:307–311PubMedCrossRef

19.

Xie JJ, Xu LY, Zhang HH, Cai WJ, Mai RQ, Xie YM, Yang ZM, Niu YD, Shen ZY, Li EM (2005) Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem Biophys Res Commun 337:355–362PubMedCrossRef

20.

Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M (2004) The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 67:262–270PubMedCrossRef

21.

Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, Iannucci A, Sonzogni A, De Manzoni G, Terzi A, Durante E, Bresaola E, Pezzella F, Viale G (2003) Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer 88:537–547PubMedCrossRef

22.

Tong GX, Yee H, Chiriboga L, Hernandez O, Waisman J (2005) Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Hum Pathol 36:741–746PubMedCrossRef

23.

Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN (2003) Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 1:420–427PubMed

24.

Yan L, Zucker S, Toole BP (2005) Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93:199–204PubMed

25.

Adams JC (2004) Fascin protrusions in cell interactions. Trends Cardiovasc Med 14:221–226PubMedCrossRef

26.

Hashimoto Y, Skacel M, Adams JC (2005) Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol 37:1787–1804PubMedCrossRef

27.

Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, Schulick RD, Yeo CJ, Rahman A, Hinkle DA, Hruban RH, Argani P (2004) Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 35:357–366PubMedCrossRef

28.

Jawhari AU, Buda A, Jenkins M, Shehzad K, Sarraf C, Noda M, Farthing MJ, Pignatelli M, Adams JC (2003) Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 162:69–80PubMed

29.

Hu W, McCrea PD, Deavers M, Kavanagh JJ, Kudelka AP, Verschraegen CF (2000) Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin Exp Metastasis 18:83–88PubMedCrossRef

30.

Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M (2006) Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56:359–367PubMedCrossRef

Title: Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters
Authors: Wen-Chiuan Tsai
Lai-Fa Sheu
Shin Nieh
Cheng-Ping Yu
Gung-Huan Sun
Yeh-Feng Lin
Ann Chen
Jong-Shiaw Jin
Publication date: 01-03-2007
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 1/2007
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-006-0110-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2007

Treatment of localized prostate cancer

Biopsy standards for detection of prostate cancer

Percutaneous radiotherapy for low-risk prostate cancer: options for 2007

Basic principles of anatomy for optimal surgical treatment of prostate cancer

Role of lymphadenectomy in clinically organ-confined prostate cancer

Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2–10 ng/ml in 4,480 men